Senior Leadership Team
Dr Martin Graham joined the Empire Discovery Institute in April 2019. He is a successful drug developer and serial entrepreneur with over 30 years of experience in the development of small molecule drugs and biologics including Oxaliplatin (colorectal cancer), Stelara (psoriasis), Remicade (rheumatoid arthritis & Crohn’s disease and Elitek (rasburicase) for tumor lysis syndrome. He brings a wealth of pharmaceutical industry experience with Sterling-Winthrop, Sanofi, Centocor, Johnson & Johnson, and venture backed biotechnology companies including TetraLogic Pharmaceuticals.
Prior to joining EDI, Martin was the CEO, President and Founder of PKPD Biosciences (a pharmacokinetic modeling & simulation company) which he merged with his second company KinderPharm, a pediatric drug development company before being acquired by Synteract. Martin earned his PhD. from the University of London Drug Development Section, Institute of Cancer Research, Royal Marsden Hospital, London; his B.Sc. from the University of Leeds in Pharmacology and Microbiology; and is an Honorary Professor of Pharmacokinetic Modeling & Simulation at the School of Life Sciences, Institute of Pharmaceutical Innovation University of Bradford, England. Martin served as a Scientific Advisor to the Harrington Discovery Institute until joining EDI in 2019 and is currently a pharmacology consultant to BioMotiv, the early stage drug discovery accelerator that is part of the Harrington Project.
Martin Graham, PhD
Chief Executive Officer
Adam Tulgan joined the Empire Discovery Institute in August 2018 after spending the last 5 years at the University of Rochester in a variety of business development roles within the Medical Center and the School of Arts, Sciences & Engineering. Adam is a strong relationship builder with a history of connecting the right people with the right expertise to deliver on specific goals. He has a proven track record of establishing industry-academic collaborations between faculty, students and industry partners.
Adam is a successful academic and industry health care professional with nearly twenty years of experience in building strategic partnerships and alliances within the pharmaceutical, information technology, medical device, and academic research sectors. Adam worked for Stryker Neurovascular as a Neurovascular Regional Territory Manager in NYC managing a $3.3M territory selling hemorrhagic and acute stroke revascularization products to interventional neuro-radiologists and neuro surgeons in the Interventional Neuroradiology Suite. Prior to Stryker, he worked as a Senior Surgical Device Specialist at Covidien AutoSuture (now Medtronic) in NJ/NYC managing a $5.6M territory selling mechanical, ultrasonic, and bipolar cutting/ligation devices and surgical access devices to general, bariatric, cardiothoracic, OB/GYN, and Urology surgeons in the Operating Room. Past sales experience also include Oracle, Pfizer and a software start-up company called Thor Technologies (later acquired by Oracle).
Adam earned his M.A. from Georgetown University in Latin American Studies and Economics, Walsh School of Foreign Service and his B.A. from Rutgers University in Political Science with a minor in Spanish.
Adam Tulgan, MA
Chief Operating Officer
Dr. Ronald Newbold has over 27 years of Business Development and Alliance Management experience leading business teams in negotiating over $1.5 billion in announced pharma / biotech deals. Prior to joining EDI, Ron served as Senior Vice President and Head of US Business Development & Alliance Management, Otsuka America Pharmaceuticals, Princeton NJ.
Ron acquired significant experience in external partnering in the Life Sciences field from his previous activities in large Pharma as well as biotech companies. Ron is a PhD graduate of the University of Rochester. After completing his postdoctoral fellowship in Medicinal Chemistry at Harvard University, Ron joined Merck where he was ultimately responsible for Strategic Research Initiatives. Following 14 years with Merck, Ron was the senior business development executive at Sentigen Biosciences, Celldex Therapeutics and Auspex Pharmaceuticals.
Ron joined Pfizer in 2010 to manage a global team of scientists in over 10 countries evaluating and proposing partnerships of scientific value to broadened Pfizer’s early-stage pipeline. Ron was also responsible for starting and leading the Pfizer Seed Fund, created through an evolution of Pfizer’s Incubator. During Ron’s tenure with Pfizer, he served as Board Observer to several companies, as a member of Neomed Therapeutics Scientific Advisory Board and he remains Vice Chairman of the Licensing and Ventures Group at the University of Virginia.
Ron Newbold, PhD
Chief Business Officer
Joshua E. Gewolb JD is legal counsel for Empire Discovery Institute and is a partner at Harter, Seacrest & Emory (HSE), Rochester NY. Josh began his career as a traditional federal tax lawyer. Starting at Debevoise & Plimpton, LLP and continuing at Harter Secrest & Emery LLP, he provides advice to clients from small local enterprises to large publicly traded corporations about a full range of tax matters. He combines the intellectual background associated with a large traditional tax practice and the practical problem-solving approach required for smaller entities. Josh also looks at tax through the lens of state tax planning and has experience guiding clients through the unique issues presented in this area. He helps clients resolve audits/controversies as quickly and efficiently as possible, and this experience informs his transactional practice.
Josh counsels organizations ranging from small start-up enterprises to large national foundations on complex tax and not-for-profit law issues. His experience at the intersection of tax and not-for-profit law enables him to provide counsel on the unique issues presented by mergers and acquisitions involving not-for-profit organizations. Josh has a special expertise in the area of private foundations and serves a number of corporate and family foundations nationwide. He develops close relationships with his not-for-profit clients and many think of him as not just a lawyer but as a full member of the team helping to enhance their mission.
Josh’s comments on tax reform have been featured in The New York Times, the Wall Street Journal and Bloomberg Tax Daily Tax Report. He authors a column on tax matters, a blog on exempt organizations, and participates frequently in bar association reports. He is deeply engaged in current events in tax and non-profit law and has presented at the American Bar Association, the New York State Bar Association and at numerous local events.